CINECA IRIS Institutional Research Information System

ROMEI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.655
EU - Europa 6.577
AS - Asia 5.832
SA - Sud America 823
AF - Africa 360
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 25.261
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.357
IT - Italia 2.439
SG - Singapore 1.801
CN - Cina 1.644
DE - Germania 1.250
HK - Hong Kong 939
SE - Svezia 896
BR - Brasile 680
VN - Vietnam 503
GB - Regno Unito 377
BG - Bulgaria 321
FR - Francia 238
RU - Federazione Russa 210
CA - Canada 208
IN - India 200
CI - Costa d'Avorio 193
FI - Finlandia 193
TR - Turchia 179
AT - Austria 164
JP - Giappone 120
UA - Ucraina 115
KR - Corea 103
NL - Olanda 94
SN - Senegal 66
BD - Bangladesh 65
IQ - Iraq 50
CH - Svizzera 49
AR - Argentina 42
PL - Polonia 41
MX - Messico 39
PK - Pakistan 36
EE - Estonia 33
BE - Belgio 32
ZA - Sudafrica 32
ES - Italia 27
SA - Arabia Saudita 26
EC - Ecuador 25
ID - Indonesia 25
MA - Marocco 22
CO - Colombia 20
UZ - Uzbekistan 20
VE - Venezuela 16
GR - Grecia 15
CZ - Repubblica Ceca 14
IE - Irlanda 12
CL - Cile 11
IL - Israele 11
IR - Iran 11
JO - Giordania 11
TW - Taiwan 11
AZ - Azerbaigian 10
JM - Giamaica 10
KE - Kenya 10
PH - Filippine 10
CR - Costa Rica 9
DZ - Algeria 9
PS - Palestinian Territory 9
HU - Ungheria 8
LT - Lituania 8
PE - Perù 8
PY - Paraguay 8
RO - Romania 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
PA - Panama 7
PT - Portogallo 7
TN - Tunisia 7
EG - Egitto 6
OM - Oman 6
BY - Bielorussia 5
GT - Guatemala 5
HN - Honduras 5
MY - Malesia 5
BO - Bolivia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
LB - Libano 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
AL - Albania 3
BH - Bahrain 3
EU - Europa 3
KG - Kirghizistan 3
KZ - Kazakistan 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BJ - Benin 2
DK - Danimarca 2
GE - Georgia 2
LK - Sri Lanka 2
MM - Myanmar 2
MT - Malta 2
NI - Nicaragua 2
AI - Anguilla 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
Totale 25.237
Salva come PNG Salva come JPEG
Città #
Ashburn 1.295
Singapore 994
Hong Kong 916
Dallas 893
Fairfield 839
Woodbridge 800
Ann Arbor 696
San Jose 672
Chandler 640
Santa Clara 617
Houston 577
Milan 366
Seattle 353
Shanghai 342
Cambridge 323
Sofia 317
Beijing 316
Wilmington 280
New York 252
Abidjan 193
Los Angeles 184
Boardman 171
Serra 154
Vienna 150
Princeton 149
Ho Chi Minh City 146
Ottawa 137
Munich 134
Lauterbourg 122
Hefei 121
Jacksonville 121
Lawrence 120
Rome 120
Pisa 111
Frankfurt am Main 103
Medford 103
Tokyo 101
Florence 100
Seoul 98
Hanoi 87
Des Moines 83
London 83
Council Bluffs 81
Izmir 75
Nanjing 71
Helsinki 70
Dearborn 67
Dakar 66
Buffalo 62
Istanbul 61
Dong Ket 56
Boulder 54
Bremen 53
Redondo Beach 53
Naples 52
São Paulo 49
Redwood City 42
San Diego 42
Bologna 40
Orem 39
Lancaster 38
Bern 37
Fuzhou 37
Washington 35
Turku 32
Columbus 31
Tianjin 31
Genoa 28
Baghdad 27
Brussels 27
Düsseldorf 27
Belo Horizonte 26
Ogden 24
Phoenix 24
Atlanta 23
Grafing 23
Mumbai 23
Rio de Janeiro 23
Shenyang 23
Changsha 22
Redmond 22
Chicago 21
Nanchang 21
Toronto 21
Jüchen 20
Lucca 20
San Francisco 19
Warsaw 19
Cascina 18
Brooklyn 17
Kunming 17
Montreal 17
Palermo 17
Tashkent 17
Amsterdam 16
Hangzhou 16
Hebei 16
Johannesburg 16
Pune 16
Quanzhou 16
Totale 16.335
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.171
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 341
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 318
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 259
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 253
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 253
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 249
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 243
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 241
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 241
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 234
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 228
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 228
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 227
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 227
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 226
Targeted Therapy in Thyroid Cancer: State of the Art 225
Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology 224
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 220
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 217
Inherited variants in genes somatically mutated in thyroid cancer 217
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 215
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 214
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 214
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 210
RET point mutations in Thyroid Carcinoma 208
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 207
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 206
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 206
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 205
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 204
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 198
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 197
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 195
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 194
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 194
Genome-wide association study on differentiated thyroid cancer. 193
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 191
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 189
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 188
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 187
Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system 186
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 184
Post-surgical follow-up of differentiated thyroid cancer. 183
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk 183
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 182
The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans 180
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 178
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 178
Genetic signature of differentiated thyroid carcinoma susceptibility: a machine learning approach 177
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 177
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 177
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 177
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 177
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 176
Correction: Inherited variants in genes somatically mutated in thyroid cancer 175
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 174
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 173
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 170
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 169
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. 168
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 165
Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case-Control Studies. 165
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 165
RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults 164
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 164
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 164
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 163
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 161
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 160
null 157
RET /PTC translocations and clinico-pathological features in human papillary thyroid carcinoma 157
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 156
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 156
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2 155
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 155
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: European comments to the guidelines of the American Thyroid Association 155
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 155
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 155
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 154
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 154
Il ciglitazone induce inibizione della crescita in cellule di carcinoma midollare della tiroide (TT) verosimilmente dovuta ad un aumentata espressione di PPAR gamma 152
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 152
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 151
L’ mRNA dei recettori per HGF e EGF (c-Met e EGFR) e’ iperespresso nei tumori papillari della tiroide 150
Runs of homozygosity and inbreeding in thyroid cancer 149
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 148
null 146
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 146
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 145
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 144
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 144
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 142
Medullary thyroid carcinoma in children 141
Totale 19.777
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.050
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.050
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.610 66 84 33 104 330 186 57 82 75 64 120 409
2022/20232.618 292 394 194 199 231 281 55 208 506 43 168 47
2023/20241.871 191 170 224 128 221 265 138 106 70 55 118 185
2024/20255.166 72 214 94 335 557 516 400 292 500 633 590 963
2025/20266.474 527 930 685 525 646 501 979 301 382 565 234 199
2026/202777 77 0 0 0 0 0 0 0 0 0 0 0
Totale 25.633